Culture Biosciences Raises $80 Million Series B

<p><strong>SAN FRANCISCO<&sol;strong> &&num;8212&semi; <a href&equals;"https&colon;&sol;&sol;www&period;culturebiosciences&period;com&sol;" target&equals;"&lowbar;blank" rel&equals;"noopener">Culture Biosciences<&sol;a>&comma; a company enabling biotech firms to develop and scale manufacturing processes in the cloud&comma; announced a Series B financing of &dollar;80 million led by <a href&equals;"http&colon;&sol;&sol;www&period;npv&period;vc&sol;" target&equals;"&lowbar;blank" rel&equals;"noopener">Northpond Ventures<&sol;a>&period; <a href&equals;"https&colon;&sol;&sol;synthesis&period;capital&sol;" target&equals;"&lowbar;blank" rel&equals;"noopener">Synthesis Capital<&sol;a> also participated in the round&period; Existing investors Cultivian Sandbox Ventures&comma; The Production Board&comma; Craft Ventures&comma; E14 Fund&comma; Box Group&comma; Verily Life Sciences&comma; and Section 32 also contributed&period; Andrew Lee&comma; Ph&period;D&period;&comma; of Northpond Ventures will join Culture’s Board of Directors&period;<&sol;p>&NewLine;<p>&&num;8220&semi;Recently there’s been an explosion in the number of new companies in synthetic biology and biopharmaceuticals&comma; and large multinational corporations are also increasingly participating in this space&comma;&&num;8221&semi; said Will Patrick&comma; CEO and co-founder&comma; Culture Biosciences&period; &OpenCurlyDoubleQuote;Although demand for biomanufactured products—from food to clothing to vaccines—is surging&comma; there&&num;8217&semi;s a huge gap in the infrastructure required to produce these bioproducts at commercial scale&period;”<&sol;p>&NewLine;<p>Importantly&comma; there currently isn’t enough manufacturing capacity in the world to support this new wave of synthetic biology products&period; Today’s global capacity falls <a href&equals;"https&colon;&sol;&sol;www&period;bcg&period;com&sol;en-us&sol;publications&sol;2021&sol;the-benefits-of-plant-based-meats" target&equals;"&lowbar;blank" rel&equals;"noopener"><em>100x short<&sol;em><&sol;a> of what would be needed to meet the demand for fermentation-based animal protein in 2030&period; This major gap in large-scale capacity is what Culture is aiming to tackle for its clients looking to scale their processes up to manufacturing&comma; starting with pilot-scale bioreactors&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Demand for sustainable bio-based products is rapidly increasing&comma; but innovators face two key challenges&comma;” explained Andrew Lee&comma; Ph&period;D&period;&comma; Northpond Ventures&period; &OpenCurlyDoubleQuote;Culture’s cloud bioreactor lab already addresses the first challenge&colon; bench-scale process optimization&period; Companies still need to scale to commercial quantities&comma; however&period; By expanding its technology and data infrastructure&comma; Culture can address this growing market need&period; We’re excited at Northpond to help make that happen&period;”<&sol;p>&NewLine;<p>Since announcing a &dollar;15 million Series A in 2020&comma; Culture has grown 3x year-over-year and invested in scaling out its facilities&comma; offerings&comma; and team&period; Key achievements include&colon;<&sol;p>&NewLine;<ul>&NewLine;<li>Accelerating bioprocess development for 30&plus; of the world’s leading biotech companies<&sol;li>&NewLine;<li>Streamlining data analysis and cross-team collaboration for clients by launching Culture’s Cloud Console&comma; a one-stop web app for experiment data and insights<&sol;li>&NewLine;<li>Launching new capabilities beyond fermentation&comma; such as mammalian cell culture and analytical chemistry<&sol;li>&NewLine;<li>More than doubling full-time employee count in the past year<&sol;li>&NewLine;<&sol;ul>&NewLine;<p>To date&comma; Culture has raised over &dollar;100 million&period; This new round of funding will be used to build and scale 5L and 250L cloud bioreactors&comma; supporting customer demand for larger quantities of material to use for testing and regulatory approval&period; In a survey conducted by the company in 2020&comma; participating biopharma and synthetic biology companies indicated that&comma; out of all potential new product offerings&comma; pilot scale bioreactors would be the most beneficial to their work&period; Now&comma; Culture’s clients can develop&comma; optimize&comma; and scale their bioproducts virtually&period; Many customers are already signing up to use the larger tanks when they become available&period;<&sol;p>&NewLine;

Editor

Syncere Scores $11 Million Pre-Seed Round

PALO ALTO -- SYNCERE, a home robotics startup, has scored $11 million in pre-seed funding…

2 days

Amazon Offers Members Food Delivery From Uber Eats

SEATTLE & SAN FRANCISCO -- Amazon is teaming up with Uber to offer food delivery…

3 days

Collective Lands $100 Million in Funding

SAN FRANCISCO — Collective, a financial operating system for solo businesses, has landed $100 million…

1 week

Serval Raises $150 Million Series C

SAN FRANCISCO -- Serval, an enterprise service management and automation platform, has raised a $150…

1 week

Siri AI Expands With Five More Languages

Apple's Siri AI is expanding to more people around the world, with availability now in…

1 week

Cisco to Modernize Network at Notre Dame

SAN JOSE and SOUTH BEND, IN — Cisco and Notre Dame Athletics announced a multi-year partnership…

1 week